| Biological Information | |
|---|---|
| Background Information: | Three high affinity VEGF receptors, Flt-1 (VEGFR-1, activated by placental growth factor PlGF), KDR (Flk-1/VEGFR-2, activated by VEGF), and FLT4 (VEGF3, activated by VEGF-related protein (VRP)), have been identified. These receptors can be divided into three structural regions: seven extracellular Ig-like domains that contain the growth factor binding sites, a single polypeptide chain hydrophobic trans-membrane sequence, and intracellular cytoplasmic domains that confer the tyrosine kinase activity required for signal transduction. Tissue expression of the FLT4 receptor is found predominantly in lymphatic and microvascular endothelium and some leukemia cell lines, indicating that this receptor may be a role in the regulation of hematopoiesis.
GenBank NM_182925. The recombinant protein contains the amino acid substitutions V1128L and H1146R with reference to NM_182925. These mutations are reported in GenBank U43143 and GenBank X68203. |
| Target Class: | Kinase |
| Family: | Receptor Tyrosine Kinase |
| Accession Number: | NM_002020.3; NM_182925.3 |
| Target Name: | FLT4 |
| Target Aliases: | FLT4, PCL, VEGFR-3, FLT41, VEGFR3 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Flt-4, active
N-terminal GST-tagged recombinant, human Flt4 amino acids 800-end.
Datasheets
14-681x Datasheet
View Document